

Assessing a patient for Paxlovid (nirmatrelvir/ritonavir)

Updated 14 February 2022

Page 1 of 1

Please check www.covid19-druginteractions.org for updates.

Data are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Developed by Kirsteen Hill, ID/HIV/COVID Pharmacist, Dundee, Scotland and adapted by Liverpool Drug Interactions Group.

